Inulin gel with immunotherapy for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether adding an inulin gel to standard immunotherapy (ipilimumab and nivolumab) can help treat kidney cancer that has spread or cannot be removed. It is for people who have not had prior treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your kidney cancer must have clear cells or a sarcomatoid feature and have spread or is locally advanced.
- You must not have received any prior systemic therapy for metastatic disease.
- You must be able to take oral medications and have acceptable kidney, liver, and blood counts.
- You cannot have active autoimmune disease, recent infections, or use of certain drugs like high-dose steroids, probiotics, or antibiotics.
- You must agree to use effective birth control during the study and for 5 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a probiotic (CBM588) to a standard immunotherapy combination (nivolumab and ipilimumab) helps treat advanced kidney cancer. It is for people with a specific type of kidney cancer that has spread or cannot be removed with surgery, who have not had systemic treatment before.
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
This trial is testing whether adding a gut health supplement (CBM588) to the immunotherapy drug pembrolizumab can help prevent kidney cancer from returning after surgery. It is for people with certain types of kidney cancer who have not had immunotherapy before.
This trial tests whether adding a live bacteria pill (EXL01) to standard immunotherapy drugs (nivolumab and ipilimumab) helps treat advanced or metastatic kidney cancer that has clear cells. You may join if you have not had prior immunotherapy and your cancer has not been treated before (except possibly after surgery).
This trial tests giving the drug ivonescimab before surgery for patients with high-risk clear cell kidney cancer. The goal is to see if it can help shrink the tumor and improve outcomes.
This trial tests two immunotherapy drugs (botensilimab and balstilimab) given before surgery to remove a kidney tumor. The goal is to see if this approach is safe and helps shrink tumors in patients with advanced but non-spreading kidney cancer.
Hear when a new Metastatic Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.